Company Analysis
Sign in

Intellia Therapeutics, Inc. (NTLA)

Nasdaq: NTLA · In Vitro & In Vivo Diagnostic Substances · Cambridge, MA · filing with the SEC since 2015
Full chart Alerts Compare
Grade6.0
◀ Past 6.9● Present 5.9▶ Future 5.4
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

15 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Intellia Therapeutics, Inc.’s names, not what it holds today.

Patents granted
15
15 utility, 1976 to Dec 31, 2025
Granted in 2025
4
Against 4 in 2024 and 5 in 2023
Applications published
82
18 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology11
Pharmaceuticals3
Organic fine chemistry1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Intellia Therapeutics, Inc. its own name
US, as the owner printed on each patent. 2 more under the same name are not counted (printed in GB)
15 granted
49 published
Intellia Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
33 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Nov 25, 202512,480,109Compositions and methods for kallikrein (KLKB1) gene editingBiotechnologyIntellia Therapeutics, Inc.
Nov 4, 202512,460,205Compositions and methods for treating alpha-1 antitrypsin deficiencyPharmaceuticalsIntellia Therapeutics, Inc.
Aug 19, 202512,391,722Stabilized nucleic acids encoding messenger ribonucleic acid (mRNA)BiotechnologyIntellia Therapeutics, Inc.
Feb 4, 202512,214,023Compositions and methods for expressing factor IXBiotechnologyIntellia Therapeutics, Inc.
Dec 24, 202412,173,284Modified guide RNAsBiotechnologyIntellia Therapeutics, Inc.
Sep 3, 202412,077,483Modified amine lipidsOrganic fine chemistryIntellia Therapeutics, Inc.
Jul 16, 202412,037,583Compositions and methods for immunooncologyPharmaceuticalsIntellia Therapeutics, Inc.
Apr 23, 202411,965,165Compositions and methods for TTR gene editing and treating ATTR amyloidosisBiotechnologyIntellia Therapeutics, Inc.
Dec 26, 202311,851,659Compositions and methods for immunooncologyBiotechnologyIntellia Therapeutics, Inc.
Oct 24, 202311,795,460Compositions and methods for TTR gene editing and treating ATTR amyloidosisBiotechnologyIntellia Therapeutics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 11, 20252025/0375537Systems and Methods for Genomic EditingBiotechnologyIntellia Therapeutics, Inc.
Nov 13, 20252025/0346625Stabilized Nucleic Acids Encoding Messenger Ribonucleic Acid (mRNA)BiotechnologyIntellia Therapeutics, Inc.
Oct 9, 20252025/0313845Compositions and Methods for Proprotein Convertase Subtilisin Kexin 9 (PCSK9) EditingBiotechnologyIntellia Therapeutics, Inc.
Oct 2, 20252025/0302874CD38 COMPOSITIONS AND METHODS FOR IMMUNOTHERAPYMedical technologyIntellia Therapeutics, Inc.
Sep 4, 20252025/0276090Methods and Compositions for Genetically Modifying a CellBiotechnologyIntellia Therapeutics, Inc.
Sep 4, 20252025/0276017Compositions and Methods for Genomic EditingBiotechnologyIntellia Therapeutics, Inc.
Aug 28, 20252025/0269062METHODS FOR IN VIVO EDITING OF A LIVER GENEPharmaceuticalsIntellia Therapeutics, Inc.
Aug 28, 20252025/0268940CHIMERIC ANTIGEN RECEPTOR COMPOSITIONS AND USESBiotechnologyIntellia Therapeutics, Inc.
Aug 21, 20252025/0262302Compositions and Methods for Reducing MHC Class I in a CellBiotechnologyIntellia Therapeutics, Inc.
Aug 14, 20252025/0255940COMPOSITIONS AND METHODS FOR EXPRESSING FACTOR IXBiotechnologyIntellia Therapeutics, Inc.
What it applied for, 2024 to 2025: Biotechnology 26 · Medical technology 4 · Pharmaceuticals 3 · Organic fine chemistry 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton NTLA · research, not advice